劉 濤 張俊會(huì) 李 娜
1.河北省民政總醫(yī)院內(nèi)四科,河北邢臺(tái)054000;2.邢臺(tái)醫(yī)學(xué)高等??茖W(xué)校病理教研室,河北邢臺(tái)054000
木犀草素對(duì)糖尿病腦梗死大鼠神經(jīng)細(xì)胞凋亡及HSP70 mRNA、Fas mRNA表達(dá)的影響
劉 濤1張俊會(huì)2▲李 娜2
1.河北省民政總醫(yī)院內(nèi)四科,河北邢臺(tái)054000;2.邢臺(tái)醫(yī)學(xué)高等??茖W(xué)校病理教研室,河北邢臺(tái)054000
目的探討木犀草素對(duì)糖尿病腦梗死大鼠神經(jīng)細(xì)胞凋亡及HSP70 mRNA、Fas mRNA表達(dá)的影響。方法Wistar大鼠60例,隨機(jī)分為對(duì)照組、模型組及木犀草素高、中、低劑量組。對(duì)照組給予常規(guī)飼料喂養(yǎng);模型組及木犀草素高、中、低劑量組采用高脂高糖飲食加腹腔注射小劑量鏈脲霉素建立糖尿病大鼠模型,造模后,木犀草素高劑量、中劑量、低劑量組每日分別給予木犀草素200、100、50 mg/kg灌胃,模型組每日給予生理鹽水2 mL灌胃,連續(xù)8周。再以線栓法建立大鼠大腦中動(dòng)脈永久性缺血模型,術(shù)后24 h斷頭取腦,用TUNEL法和原位雜交法觀察大鼠腦細(xì)胞凋亡與腦組織HSP70 mRNA及Fas mRNA的表達(dá)。結(jié)果木犀草素低、中、高劑量組糖尿病腦梗死神經(jīng)細(xì)胞凋亡數(shù)分別為(16.42±1.39)、(11.08±2.15)、(9.25±1.98)個(gè)/高倍視野低于模型組[(29.75±2.36)個(gè)/高倍視野],組間差異有統(tǒng)計(jì)學(xué)意義(均P<0.01);HSP70 mRNA在模型組表達(dá)[(9.75±2.766)個(gè)/高倍視野]顯著高于對(duì)照組[(0個(gè)/高倍視野)](P<0.01);低、中、高三個(gè)劑量的木犀草素組HSP70 mRNA表達(dá)分別為(11.33±2.15)、(13.92± 2.15)、(14.92±1.95)個(gè)/高倍視野,均高于模型組[(9.75±2.76)個(gè)/高倍視野](均P<0.01);Fas mRNA在模型組大鼠腦組織陽性細(xì)胞數(shù)[(25.33±3.17)個(gè)/高倍視野]顯著高于對(duì)照組[(2.67±0.95)個(gè)/高倍視野](P<0.01);高、中、低劑量木犀草素組大鼠腦組織Fas mRNA陽性細(xì)胞數(shù)分別為(11.92±2.41)、(12.00±2.50)、(19.75±2.54)個(gè)/高倍視野,顯著低于模型組[(25.33±3.17)個(gè)/高倍視野](均P<0.01)。結(jié)論木犀草素可以抑制糖尿病腦梗死大鼠神經(jīng)細(xì)胞凋亡,其機(jī)制與木犀草素升高大鼠腦組織HSP70 mRNA表達(dá),同時(shí)使Fas mRNA的表達(dá)降低有關(guān)。
糖尿?。荒X梗死;木犀草素;HSP70 mRNA;Fas mRNA
缺血性腦損傷后會(huì)出現(xiàn)多種病理改變,壞死是引起梗死中心區(qū)神經(jīng)細(xì)胞死亡的主要原因,而凋亡則是導(dǎo)致梗死半暗帶區(qū)神經(jīng)細(xì)胞死亡的主要因素[1]。凋亡細(xì)胞主要存在于半暗帶區(qū),因而凋亡能夠影響最后腦梗死的面積[2]。HSP70是一種細(xì)胞內(nèi)源性保護(hù)蛋白,主要參與機(jī)體耐受的形成[3-4],有抑制細(xì)胞凋亡的作用,而Fas基因是促進(jìn)細(xì)胞凋亡的重要基因[5-6]。木犀草素(Luteolin)最初是從草本植物木犀草的葉、莖、枝中被分離出而得名,其具有抗炎、抗氧化、抑制凋亡、抗過敏、抗腫瘤等多種生物學(xué)作用。為此,本實(shí)驗(yàn)在于觀察木犀草素對(duì)糖尿病腦梗死大鼠神經(jīng)細(xì)胞凋亡及HSP70 mRNA、Fas mRNA表達(dá)的影響,以探討木犀草素對(duì)糖尿病腦梗死大鼠腦損傷的保護(hù)機(jī)制。
1.1 實(shí)驗(yàn)動(dòng)物、試劑和藥品
雄性Wistar大鼠60只,體重180~230 g。來源于北京維通利華實(shí)驗(yàn)動(dòng)物技術(shù)有限公司,生產(chǎn)許可證:SCXK(京)2009-0003。細(xì)胞凋亡檢測(cè)試劑盒(TUNEL)、HSP70及Fas原位雜交試劑盒均購(gòu)于武漢博士德生物技術(shù)公司;木犀草素(98%)購(gòu)于陜西慧科植物開發(fā)有限公司;鏈尿菌素(STZ)購(gòu)于Sigma公司。
1.2 實(shí)驗(yàn)方法
1.2.1 動(dòng)物模型制作各組均先以高脂高糖飼料喂養(yǎng)4周,然后以STZ(30 mg/kg)腹腔注射1次,72 h后尾靜脈采血測(cè)定血糖,空腹血糖>16.7 mol/L的大鼠判定為造模成功。以線栓法制作大鼠右側(cè)大腦中動(dòng)脈閉塞(MCAO)模型[7]。大鼠成功麻醉后,頸部正中切口,暴露并鈍性游離右側(cè)頸總動(dòng)脈(CCA)、頸外動(dòng)脈及頸內(nèi)動(dòng)脈,結(jié)扎同側(cè)CCA近心端和頸外動(dòng)脈(ECA)分叉部,距頸總動(dòng)脈分叉處近心端5 mm處剪口,選用頭端燒成光滑杵狀的國(guó)產(chǎn)尼龍線插入頸內(nèi)動(dòng)脈,以頸總動(dòng)脈分叉處計(jì)算進(jìn)線深度為18 mm左右,至大腦中動(dòng)脈起始部以完全阻斷血供,結(jié)扎頸內(nèi)動(dòng)脈并固定魚線。術(shù)中,用加熱墊和燈泡保持肛溫在37.0~37.5℃。
1.2.2 動(dòng)物分組及處理60只Wistar大鼠,隨機(jī)分為5組:對(duì)照組、模型組及木犀草素高、中、低劑量組,每組各12只。糖尿病性動(dòng)物模型制備后,開始灌胃給藥,木犀草素高劑量、中劑量、低劑量組每日分別給予木犀草素200、100、50 mg/kg灌胃,模型組與對(duì)照組每日給予生理鹽水2 mL灌胃,連續(xù)8周。每組大鼠于MCAO術(shù)后24 h斷頭取腦,用TUNEL法和原位雜交法觀察大鼠腦細(xì)胞凋亡與腦組織HSP70 mRNA及Fas mRNA的表達(dá)。
1.2.3 原位凋亡細(xì)胞檢測(cè)各實(shí)驗(yàn)組大鼠斷頭取腦后,將腦組織置于4%的多聚甲醛溶液固定,石蠟包埋,做連續(xù)切片,切片厚度為5 μm。TUNEL染色按試劑盒說明操作,細(xì)胞核中有棕褐色顆粒者為TUNEL陽性細(xì)胞,細(xì)胞計(jì)數(shù)于高倍鏡(40×10)下隨機(jī)選取5個(gè)視野,計(jì)數(shù)陽性細(xì)胞數(shù),取平均值。
1.2.4 HSP70 mRNA及Fas mRNA測(cè)定采用原位雜交法,操作步驟嚴(yán)格按照說明書進(jìn)行,DAB顯色蘇木素復(fù)染。陽性判斷標(biāo)準(zhǔn):HSP70 mRNA及Fas mRNA表達(dá)于細(xì)胞漿,以棕黃色顆粒為陽性。以高倍鏡(40× 10)觀察5個(gè)視野,計(jì)數(shù)陽性細(xì)胞數(shù)。
1.3 統(tǒng)計(jì)學(xué)方法
采用SPSS 11.5統(tǒng)計(jì)軟件進(jìn)行統(tǒng)計(jì)分析,計(jì)量資料數(shù)據(jù)以均數(shù)±標(biāo)準(zhǔn)差(x±s)表示,各組間比較采用方差分析,組間兩兩比較,采用LSD-t檢驗(yàn)。計(jì)數(shù)資料以率表示,采用χ2檢驗(yàn)。以P<0.05為差異有統(tǒng)計(jì)學(xué)意義。
2.1 各組大鼠腦組織中凋亡細(xì)胞數(shù)
TUNEL陽性細(xì)胞分布在腦梗死半暗帶區(qū),形態(tài)學(xué)上表現(xiàn)為胞核固縮,呈棕褐色。本實(shí)驗(yàn)中對(duì)照組無凋亡細(xì)胞,模型組凋亡細(xì)胞數(shù)顯著高于對(duì)照組(P<0.01);木犀草素高、中、低劑量三組凋亡細(xì)胞數(shù)均低于模型組,組間差異有統(tǒng)計(jì)學(xué)意義(均P<0.01);木犀草素三組中隨藥物劑量加大凋亡細(xì)胞數(shù)逐漸減少,高、中劑量組及中、低劑量組間差異有統(tǒng)計(jì)學(xué)意義(均P<0.01)。見表1。
2.2 各組大鼠腦組織中HSP70 mRNA、Fas mRNA的表達(dá)
對(duì)照組HSP70 mRNA無表達(dá),模型組HSP70 mRNA的表達(dá)顯著高于對(duì)照組(P<0.01);低、中、高三個(gè)劑量的木犀草素組HSP70 mRNA表達(dá)均高于模型組(均P<0.01)。高、中劑量木犀草素組之間及中、低劑量劑量木犀草素組之間比較差異均有統(tǒng)計(jì)學(xué)意義(均P<0.01)。Fas mRNA在模型組大鼠腦組織陽性表達(dá)高于對(duì)照組,組間差異有統(tǒng)計(jì)學(xué)意義(P<0.01);高、中、低劑量木犀草素組大鼠腦組織Fas mRNA陽性細(xì)胞數(shù)顯著低于模型組(均P<0.01);高、中劑量木犀草素組大鼠腦組織Fas mRNA陽性細(xì)胞數(shù)顯著低于小劑量木犀草素組(均P<0.01)。見表1。
表1 糖尿病大鼠腦梗死后各組凋亡細(xì)胞、HSP70 mRNA及Fas mRNA陽性細(xì)胞數(shù)的比較(個(gè)/HD,x±s)
腦梗死后亞急性期和慢性期病變進(jìn)一步加重的重要原因之一是神經(jīng)元遲發(fā)性死亡,急性腦缺血缺氧損傷后繼發(fā)的細(xì)胞凋亡是遲發(fā)性神經(jīng)元死亡的主要方式[8-9]。細(xì)胞凋亡不同于細(xì)胞壞死,又稱為程序性死亡,是機(jī)體清除衰老和損傷的細(xì)胞以保持內(nèi)環(huán)境平衡的一種自我調(diào)節(jié)機(jī)制。腦缺血后,缺血中心區(qū)神經(jīng)元細(xì)胞因?yàn)橥耆毖l(fā)生不可逆轉(zhuǎn)地死亡,缺血周邊區(qū)尤其是缺血半暗帶內(nèi)因多種病理因素而激活凋亡通路,使細(xì)胞呈現(xiàn)凋亡的形態(tài)學(xué)改變。因此挽救半暗帶內(nèi)受損的神經(jīng)元,對(duì)治療缺血性腦血管疾病就顯得尤為重要。細(xì)胞凋亡受一系列基因的調(diào)控,HSP70與Fas基因是與細(xì)胞凋亡有關(guān)的兩個(gè)重要基因。HSP70在正常大鼠腦內(nèi)并不存在,但在腦缺血、缺氧等誘導(dǎo)下其表達(dá)增加,HSP70的高表達(dá)是腦受到保護(hù)的標(biāo)志[10]。而Fas基因是重要的促凋亡因子。本實(shí)驗(yàn)發(fā)現(xiàn)對(duì)照組大鼠腦內(nèi)無HSP70 mRNA陽性細(xì)胞,表明在正常情況下腦內(nèi)無HSP70 mRNA的表達(dá)。在糖尿病腦梗死模型組大鼠腦組織中HSP70 mRNA表達(dá)增強(qiáng),與對(duì)照組比較差異有統(tǒng)計(jì)學(xué)意義;對(duì)照組大鼠腦內(nèi)有少數(shù)Fas mRNA陽性細(xì)胞,在模型組大鼠腦組織中Fas mRNA表達(dá)增強(qiáng),與對(duì)照組比較差異有統(tǒng)計(jì)學(xué)意義。
神經(jīng)細(xì)胞凋亡是一遲發(fā)性病變,因而尋求抑制腦缺血后神經(jīng)元過度凋亡的有效藥物是實(shí)現(xiàn)腦缺血后腦保護(hù)的一條重要途徑。木犀草素是存在于多種植物中的天然黃酮類化合物,具有包括抗凋亡在內(nèi)的多種生物作用。已有研究證明,木犀草素對(duì)大鼠早期糖尿病心肌病及實(shí)驗(yàn)性糖尿病大鼠的腎臟有保護(hù)作用[11-14]。本實(shí)驗(yàn)結(jié)果顯示低、中、高劑量木犀草素組HSP70 mRNA陽性細(xì)胞數(shù)明顯高于模型組;而三種劑量的木犀草素組大鼠腦組織Fas mRNA陽性細(xì)胞數(shù)顯著低于模型組;同時(shí)該實(shí)驗(yàn)凋亡細(xì)胞數(shù)檢測(cè)顯示,模型組凋亡細(xì)胞數(shù)顯著高于對(duì)照組;木犀草素高、中、低劑量三組凋亡細(xì)胞數(shù)均低于模型組,組間差異有統(tǒng)計(jì)學(xué)意義;木犀草素三組中隨藥物劑量加大凋亡細(xì)胞數(shù)逐漸減少,顯示有劑量依賴性。此結(jié)果提示木犀草素可增強(qiáng)HSP70 mRNA的表達(dá),同時(shí)使Fas mRNA的表達(dá)減少,從而抑制腦缺血后神經(jīng)細(xì)胞凋亡,達(dá)到對(duì)糖尿病腦梗死的腦組織的保護(hù)作用。
[1]BenchouaA,GueganC,CouriaudC,etal.Specificcaspasepathways are activated in two stages of cerebral infarction[J].J Neurosci,2001,21(18):7127-7134.
[2]Guegan C,Boutin H,Boudry C,et al.Apoptotic death in cortical neurons of mice subjected to focal ischemia[J].C R Acad SciⅢ,1996,319(10):879-885.
[3]Brodsky JL,Chiosis G.HSP70 molecular chaperones:emerging roles in human disease and identification of small mole cule modulatots[J].Curr Top Med Chem,2006,6:1215-25
[4]Schoelzke,Marion N,Schwaninger.Markus transcriptional regulation of neurogenesis:potential mechanisms in cerebral ischemia[J].Journal of Molecular Medicine(Berlin),2007,85(6):577-588.
[5]Lee P,Sata M,Lefer DJ,et al.Fas pathway is a critical mediator of cardiac myocyte death and MI during ischemia-reperfusion in vivo[J].Am J Physiol Heart Circ Physiol,2003,284(2):456-463.
[6]Li HZ,Han LP,Jiang CM,et al.Effect of dopamine receptor-1 on apoptosis of cultured neonatal rat cardiomyocytes in simulated ischemia/reperfusion[J].Basic Clini Pharmacol Toxicol,2008,102(3):329-336.
[7]賈玉潔,閔連秋,季占勝,等.原花青素對(duì)腦缺血后抑凋亡基因蛋白Bcl-2和促凋亡基因蛋白Bax的影響[J].中國(guó)臨床康復(fù),2006,10(23):65-72.
[8]Culmsee C,Plesnila N.Targeting Bid to prevent programmed cell death in neurons[J].Biochem Soc Trans,2006,34(6):1334-1340.
[9]Plesnila N,Zhu C,Culmsee C.Nuclear translocation of apoptosis-inducing factor after focal cerebral ischemia[J].J Cereb Blood Flow Metab,2004,24(4):458-466.
[10]林艷婷,余涓,潘燕霞.大鼠腦缺血再灌注損傷與杏仁核基質(zhì)金屬蛋白酶29、水通道蛋白4、熱休克蛋白70的表達(dá)[J].福建醫(yī)科大學(xué)學(xué)報(bào),2007,41(3):21-23.
[11]陳小萍,徐麗,陳海英.木犀草素對(duì)早期糖尿病大鼠心肌組織中醛糖還原酶、NOS系統(tǒng)及Na+-K+-ATPase的影響[J].山西醫(yī)科大學(xué)學(xué)報(bào),2007,38(8):689-692.
[12]裘兒杰.木犀草素對(duì)實(shí)驗(yàn)性糖尿病大鼠腎臟的保護(hù)作用[J].海峽藥學(xué)2012,24(6):18-20.
[13]丁婧,王輝,余詩(shī)灝,等.肥胖大鼠模型的建立及其脂代謝相關(guān)分子機(jī)制研究[J].中國(guó)實(shí)驗(yàn)動(dòng)物學(xué)報(bào),2012,20(5):20-24.
[14]李格賓,山本一郎,新井敏郎,等.肥胖犬白細(xì)胞中相關(guān)基因及血漿生化指標(biāo)的變化[J].中國(guó)實(shí)驗(yàn)動(dòng)物學(xué)報(bào),2013,21(4):75-80.
Effects of Luteolin on nerve cell apoptosis and expression of HSP70 mRNA and fas mRNA in diabetes complicating with stroke rats
LIU Tao1ZHANG Junhui2▲LI Na2
1.Fourth Internal Medicine,General Hospital of Hebei Provincal Civil Administration,Hebei Province,Xingtai 054000,China;2.Department of Pathology,Xingtai Medical College,Hebei Province,Xingtai054000,China
Objective To investigate the effect of Luteolin on nerve cell apoptosis and expression of HSP70 mRNA and Fas mRNA in diabetes complicating with stroke rats.Methods Sixty Wistar rats were randomly divided into normal control,diabetic model,low-dose Luteolin,mid-dose Luteolin and high-dose Luteolin group.Rats of control group were given conventional feed.Rat models of diabetes mellitus of diabetic model group and low-dose Luteolin,middose Luteolin and high-dose Luteolin group were made by high sucrose,fat diet and streptozotion injection.After modeling,rats in high-dose Luteolin,mid-dose Luteolin and low-dose Luteolin group were administed daily with gastric perfusion of 200,100 and 50 mg/kg Luteolin separately for 8 weeks,at the same time,model group was given saline daily 2 mL.Models of focal cerebral infarction of rats were established by the Longa′s technique.All of the rats were killed after 24 hours,TUNEL and in situ hybridization were used to detect nerve cell apoptosis and expression of HSP70 mRNA and Fas mRNA in brain tissue of rats.Results The amount of nerve cell apoptosis in low,medium and high dose of Luteolin group of(16.42±1.39),(11.08±2.15),(9.25±1.98)/HD were lower than those of model group of (29.75±2.36)/HD,the difference was statistically significant(all P<0.01).Compared with control group of(0/HD),the expression of HSP70 mRNA in model group of(9.75±2.76)/HD significant increased.The level of HSP70 mRNA expression in low,medium and high dose of Luteolin group of(11.33±2.15),(13.92±2.15),(14.92±1.95)/HD were significant higher than those of model group of(9.75±2.76)/HD(P<0.01).The amount of Fas mRNA positive cells in model group of(25.33±3.17)/HD was higher than that of control group of(2.67±0.95)/HD(P<0.01);in high,medium and low dose of Luteolin group,the amount of Fas mRNA positivecells of(11.92±2.41),(12.00±2.50),(19.75±2.54)/HD were lower than those of model group of(25.33±3.17)/HD(P<0.01).Conclusion Luteolin can inhibit nerve cell apoptosis of diabetic cerebral infarction rats,its mechanism may be related to increasing the expression of HSP70 mRNA and decreasing the expression of Fas mRNA,thereby reducing the apoptosis of nerve cells.
Diabetes;Infarction;Luteolin;HSP70 mRNA;Fas mRNA
R743.32
A
1673-7210(2014)01(a)-0021-03
2013-10-17本文編輯:衛(wèi)軻)
▲通訊作者